Pages that link to "Q72174351"
Jump to navigation
Jump to search
The following pages link to Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma (Q72174351):
Displaying 50 items.
- Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy (Q24186051) (← links)
- Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy (Q24240568) (← links)
- Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy (Q24243810) (← links)
- Prognostic molecular markers in early breast cancer (Q24794845) (← links)
- Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial (Q24799659) (← links)
- Whither high-dose chemotherapy in breast cancer? (Q24801121) (← links)
- Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes (Q26743510) (← links)
- Breast cancer and social environment: getting by with a little help from our friends (Q26745963) (← links)
- (Q28366611) (← links)
- Systems of protocol review, quality assurance, and data audit (Q32016096) (← links)
- Much Ado About Not ... Enough Data: High-Dose Chemotherapy With Autologous Stem Cell Rescue for Breast Cancer (Q32125096) (← links)
- Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer (Q33332252) (← links)
- An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer (Q33340401) (← links)
- Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents (Q33340623) (← links)
- Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. (Q33384061) (← links)
- Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer (Q33395708) (← links)
- Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results (Q33397922) (← links)
- Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer (Q33397995) (← links)
- The effect of chemotherapy-induced anemia on dose reduction and dose delay (Q33432161) (← links)
- Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. (Q33434223) (← links)
- Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials (Q33440431) (← links)
- Breast cancer (non-metastatic) (Q33446778) (← links)
- Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support (Q33488249) (← links)
- The present and future of hematopoietic cytokines in clinical practice (Q33489326) (← links)
- Chemo-Radiotherapy For Localized Pancreatic Cancer: Increased Dose Intensity and Reduced Acute Toxicity with Concomitant Radiotherapy and Protracted Venous Infusion 5-Fluorouracil (Q33501264) (← links)
- Locally advanced breast cancer (Q33654588) (← links)
- Postmastectomy radiation in patients with one to three positive axillary nodes receiving adjuvant chemotherapy: An unresolved issue (Q33667584) (← links)
- Current status of androgen suppression and radiotherapy for patients with prostate cancer (Q33694978) (← links)
- High dose therapy of breast cancer: current status (Q33706206) (← links)
- Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment (Q33731778) (← links)
- Autologous stem-cell transplantation for solid tumors in adults (Q33769684) (← links)
- Adjuvant systemic therapy for primary breast cancer (Q33779184) (← links)
- High-dose chemotherapy: is it standard management for any common solid tumor? (Q33787443) (← links)
- Optimising chemotherapy dose density and dose intensity. new strategies to improve outcomes in adjuvant therapy for breast cancer (Q33900910) (← links)
- The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? (Q33900916) (← links)
- A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care (Q33900921) (← links)
- Multidisciplinary care for patients with breast cancer (Q33932014) (← links)
- High dose chemotherapy: rationale and results in breast carcinoma (Q33970577) (← links)
- Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. (Q33984071) (← links)
- Randomized trials of high dose chemotherapy for breast cancer. (Q34183739) (← links)
- The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours (Q34338018) (← links)
- Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk (Q34354614) (← links)
- The epidermal growth factor receptor family in breast cancer (Q34363400) (← links)
- Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials (Q34436046) (← links)
- Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers (Q34623400) (← links)
- Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. (Q35019658) (← links)
- Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome (Q35024456) (← links)
- Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia (Q35024477) (← links)
- Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis (Q35041302) (← links)
- Recent advances in the systemic therapy of breast cancer. (Q35052282) (← links)